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Abstract
© 2017,  Nizhny  Novgorod  State  Medical  Academy.  All  rights  reserved.  The  aim  of  the
investigation was to evaluate experimentally the role of the P2 receptor-mediated component in
neurogenic tone control of human varicose-affected and healthy great saphenous vein (GSV).
Materials and Methods. The material for the study were segments of GSV obtained from two
groups of patients: group 1 (n=14) included patients with varicose vein disease, in whom GSV
was removed during surgical  treatment;  group 2 (n=21) comprised patients with coronary
artery disease who underwent coronary artery bypass grafting using GSV as an autograft.
Mechanical activity of the isolated veins was studied in vitro by electrical stimulation before and
after  incubation  with  atropine  and  phentolamine,  pyridoxal-phosphate-6-azophenyl-  2’,4’-
disulfonate (PPADS) and suramin (both nonselective antagonists of P2 receptors), and also after
desensitization of P2X receptors by a,ß-methylene ATP. Results. Atropine and phentolamine did
not completely inhibit  the contractile  responses evoked by electric  field stimulation of  the
varicose  and  non-varicose  GSV.  PPADS  (10  and  30  µM)  and  suramin  (100  and  300  µM)
significantly reduced the contractile amplitude of GSV response in both groups of veins (p <
0.05) in  the presence of  atropine and phentolamine.  α,  β-methylene ATP (10 µM) did not
significantly  reduce  the  amplitude  of  the  GSV  contractile  response  (p  >  0.05).  Atropine,
phentolamine and PPADS inhibited the contractile responses to a lesser extent in the varicose-
affected  veins  compared  to  the  veins  unaffected  by  varicose  disease.  Conclusion.  These
experimental  results  suggest  the presence of  the P2 receptor-mediated component  in  the
neurogenic control of human GSV tone. Further studies of the P2 receptor mechanism of action
is promising for the development of drugs both for treating varicose veins and for preventing
spasm of the venous grafts after aortocoronary bypass surgery.
http://dx.doi.org/10.17691/stm2017.9.1.10
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